A5101428031- Lung Cancer Treatments and Mutations
- Bladder and Urothelial Cancer Treatments
- Gastric Cancer Management and Outcomes
- Transcranial Magnetic Stimulation Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Natural product bioactivities and synthesis
- Traditional Chinese Medicine Analysis
- Pharmacological Effects of Natural Compounds
- Traumatic Brain Injury Research
- Microbial Metabolism and Applications
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- Antioxidant Activity and Oxidative Stress
- HER2/EGFR in Cancer Research
- Nanoparticle-Based Drug Delivery
- Computational Drug Discovery Methods
- Radiomics and Machine Learning in Medical Imaging
- Muscle activation and electromyography studies
- Neurological Disease Mechanisms and Treatments
- Lymphoma Diagnosis and Treatment
- Stroke Rehabilitation and Recovery
- Lung Cancer Diagnosis and Treatment
Weifang People's Hospital
2012-2025
Beijing University of Chinese Medicine
2016-2025
Qingdao University
2008-2025
Yuhuangding Hospital
2008-2025
University of Science and Technology of China
2025
Hefei National Center for Physical Sciences at Nanoscale
2025
Nanchang University
2006-2024
First Affiliated Hospital of Jiangxi Medical College
2023-2024
Zhejiang Institute of Hydraulics & Estuary
2024
Xian Yang Central Hospital
2024
Abstract Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E, in patients HER2+ locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies. Patients Methods: This was phase II, open-label, multicenter, single-arm study (IHC status 3+ 2+) mUC who previously failed at least one line systemic chemotherapy. The primary endpoint objective response rate (ORR) assessed by blinded...
Abstract Background Current treatment options for human epidermal growth factor receptor 2 (HER2)‐overexpressing gastric cancer at third‐line have shown limited clinical benefit. Further, there is no specific HER2 immunohistochemistry (IHC) 2+ and fluorescence in‐situ hybridization‐negative patients. Here, we report the efficacy safety of a novel anti‐HER2 antibody RC48 patients with HER2‐overexpressing, advanced or gastroesophageal junction cancer. Methods Patients HER2‐overexpressing (IHC...
Importance Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition chemotherapy remains unknown. Objective To determine whether toripalimab in platinum-based will improve event-free survival major pathological response stage II or III resectable NSCLC compared alone. Design, Setting, Participants This randomized trial enrolled (without EGFR ALK...
To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard regular therapies.
Immunochemotherapy is the first-line standard for extensive-stage small-cell lung cancer (ES-SCLC). Combining regimen with anti-angiogenesis may improve efficacy. ETER701 was a multicenter, double-blind, randomized, placebo-controlled phase 3 trial that investigated efficacy and safety of benmelstobart (a novel programmed death-ligand 1 (PD-L1) inhibitor) anlotinib multi-target anti-angiogenic small molecule) chemotherapy in treatment-naive ES-SCLC. The assessed two primary endpoints:...
Zuojinwan (ZJW), a classic herbal formula, has been extensively used to treat gastric symptoms in clinical practice China for centuries. However, the pharmacological mechanisms of ZJW still remain vague date. In present work, network pharmacology-based strategy was proposed elucidate its underlying multi-component, multi-target, and multi-pathway mode action against gastritis. First we collected putative targets based on TCMSP STITCH databases, containing interactions between known...
Carthamus tinctorius L. is widely used in traditional Chinese medicines for the treatment of cardiovascular disease. However, our current understanding molecular mechanisms supporting its clinical application still lags behind. In this study, a systems pharmacology approach integrating drug-likeness evaluation, oral bioavailability prediction, target exploration, GO enrichment analysis, KEGG pathway performance and network construction was adopted to explore therapeutic mechanism. A total 21...
Abstract Background: TROP2 (trophoblast cell surface antigen 2) is commonly over-expressed in non-small lung cancer (NSCLC) and associated with poor prognosis. SKB264 (MK-2870) a ADC developed novel linker to conjugate the payload, belotecan-derivative topoisomerase I inhibitor. The affected by both extracellular pH-sensitive cleavage intracellular enzymatic within tumor cells, which leads efficiently release payload inside cells as well microenvironment exert its anti-tumor effects. Here,...
Abstract This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals China. Adults who were histologically diagnosed and never treated for extensive-stage small cell lung cancer (ES-SCLC) enrolled. Eligible Patients randomly assigned (1:1) to receive four cycles (21 days as one cycle) of intravenous carboplatin (area under the curve 5 mg/mL per min, day 1 each etoposide (100 mg/m² body-surface area, on 1–3 with...
Network pharmacology-based identification of key pharmacological pathways Yin–Huang–Qing–Fei capsule acting on chronic bronchitis Guohua Yu,1,2,* Yanqiong Zhang,2,* Weiqiong Ren,3 Ling Dong,1 Junfang Li,2,4 Ya Geng,2,5 Yi Zhang,2 Defeng Li,2 Haiyu Xu,2 Hongjun Yang2 1School Chinese Materia Medica, Beijing University Medicine, 2Institute China Academy Medical Sciences, Beijing, 3The First Affiliated Hospital Hunan Traditional Changsha, 4School Tianjin Tianjin, 5School Basic Shandong Jinan,...
Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small-scale study. Here, we conducted multicenter, randomized, phase 3 study to compare safety cisplatin plus (LP) versus gemcitabine (GP) as first-line treatment or metastatic LSCC.Patients enrolled were aged between 18 75 years, had (clinical stage IIIB, ineligible for concurrent chemoradiation surgery) (Stage IV)...
Cancer-associated fibroblasts (CAFs) are a major component of the tumor microenvironment (TME). In hepatocellular carcinoma (HCC), quiescent hepatic stellate cells (HSCs) could be activated to become CAFs, which play critical role in progression and drug resistance. Therefore, recent efforts have been focused on combining anti-HSC pro-apoptotic activities improve anti-tumor efficacy drugs. this study, glycyrrhetinic acid hyaluronic acid–modified liposomes (GA-HA-Lip) were prepared for...
Abstract Hydrogels are formed of crosslinked polymer chains arranged in three-dimensional (3D) networks. These have good water-containing capacity and soft malleable. biocompatibility due to their significant water content, flexible structure, numerous holes. characteristics make them analogous biological tissues. Despite the publication 8700 literature related hydrogel biomedical applications past 52 years (1973 ~ 2024), studies on use hydrogels biomedicine few. To gain a comprehensive...
Neuroinflammation is a significant driving force in the pathogenesis and progression of central nervous system (CNS) disorders. Polymethoxylated flavones (PMFs), key lipid-soluble constituents Citri Reticulatae Pericarpium (CRP), exhibit excellent blood-brain barrier permeability anti-inflammatory properties, holding therapeutic potential for CNS However, specific bioactive components effects PMFs treating disorders are not well understood. This study employed comprehensive sequential...
Abstract Epithelial cell adhesion molecule (EpCAM), a tumor antigen for antibody–drug conjugates (ADCs), is highly expressed in many epithelial cancers. However, the clinical progress of EpCAM ADCs has been challenging, primarily due to their toxicity normal high-expression tissues such as gastrointestinal tract. CLDN3 co-expressed with various human malignancies, coupled its minimal presence tissues, rendering it an ideal target developing potent therapeutic ADCs. Here, we developed...
The BRIGHT-2 study (NCT05077449) is a randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of bireociclib plus fulvestrant (BF) vs. placebo (F) in Chinese female patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) who had progressed on or after prior endocrine therapy (ET). Interim results were analyzed 70% progression-free survival (PFS) events across 64 centers China between December 8, 2021, March 28,...